Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation

References

• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61:183-203; PMID:21521830; http://dx.doi.org/10.3322/caac.20113.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009; 3:97-137; PMID:19383374; http://dx.doi.org/10.1016/j.molonc.2009.02.004
   PubMed Web of Science ®Google Scholar
• Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81:214-8; PMID:10188721; http://dx.doi.org/10.1002/(SICI)1097-0215(19990412)81:2%3c214::AID-IJC8%3e3.0.CO;2-L.
   PubMed Web of Science ®Google Scholar
• Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30:4409-4415; PMID:23091106; http://dx.doi.org/10.1200/JCO.2012.43.2278
   PubMed Web of Science ®Google Scholar
• Shih I, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-8; PMID:15111296; http://dx.doi.org/10.1016/S0002-9440(10)63708-X
   PubMed Web of Science ®Google Scholar
• Cho KR, Shih I. Ovarian cancer. Annu Rev Pathol 2009; 4:287-313; PMID:18842102; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092246
   PubMed Web of Science ®Google Scholar
• Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008; 27:161-74; PMID:18317227
   PubMed Web of Science ®Google Scholar
• Prat J. Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460:237-249; PMID:22322322; http://dx.doi.org/10.1007/s00428-012-1203-5
   PubMed Web of Science ®Google Scholar
• Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is an imported disease: Fact or fiction? Curr Obstet Gynecol Rep 2012; 1:1-9; PMID:22506137; http://dx.doi.org/10.1007/s13669-011-0004-1
   PubMedGoogle Scholar
• Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; PMID:19752007; http://dx.doi.org/10.1093/carcin/bgp220
   PubMed Web of Science ®Google Scholar
• Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, Guirguis A, Krivak TC, Brody LC, Elnitski L. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One 2012; 7:e32941; PMID:22403726; http://dx.doi.org/10.1371/journal.pone.0032941
   PubMed Web of Science ®Google Scholar
• Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, et al. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One 2010; 5:e9359; PMID:20179752; http://dx.doi.org/10.1371/journal.pone.0009359
   PubMed Web of Science ®Google Scholar
• Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008; 1:47-8794-1-47; PMID:18237448; http://dx.doi.org/10.1186/1755-8794-1-47
   PubMed Web of Science ®Google Scholar
• Maradeo ME, Cairns P. Translational application of epigenetic alterations: Ovarian cancer as a model. FEBS Lett 2011; 585:2112-20; PMID:21402071; http://dx.doi.org/10.1016/j.febslet.2011.03.016
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Jones A, Teschendorff AE. Epigenetics makes its mark on women-specific cancers–an opportunity to redefine oncological approaches? Gynecol Oncol 2013; 128:134-43; PMID:23036354; http://dx.doi.org/10.1016/j.ygyno.2012.09.027
   PubMed Web of Science ®Google Scholar
• Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: Epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003-11; PMID:19574400; http://dx.doi.org/10.1210/en.2009-0404
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10.1038/nature10166
   PubMed Web of Science ®Google Scholar
• Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Jarvinen HJ, Mecklin JP, Butzow R, Peltomaki P. Distinct molecular profiles in lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer 2013; 133:2596-608; PMID:23716351
   PubMed Web of Science ®Google Scholar
• Dewdney SB, Rimel BJ, Thaker PH, Thompson DM, Jr, Schmidt A, Huettner P, Mutch DG, Gao F, Goodfellow PJ. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res 2011; 17:2120-9; PMID:21372219; http://dx.doi.org/10.1158/1078-0432.CCR-10-2668
   PubMed Web of Science ®Google Scholar
• Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28:209-18; PMID:18836486; http://dx.doi.org/10.1038/onc.2008.374
   PubMed Web of Science ®Google Scholar
• Wu Y, Halverson G, Basir Z, Strawn E, Yan P, Guo SW. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 2005; 193:371-80; PMID:16098858; http://dx.doi.org/10.1016/j.ajog.2005.01.034
   PubMed Web of Science ®Google Scholar
• Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16:1119-28; PMID:20145172; http://dx.doi.org/10.1158/1078-0432.CCR-09-2642
   PubMed Web of Science ®Google Scholar
• Myers AP, Corson LB, Rossant J, Baker JC. Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol 2004; 24:4255-66; PMID:15121846; http://dx.doi.org/10.1128/MCB.24.10.4255-4266.2004
   PubMed Web of Science ®Google Scholar
• Bornstein P, Sage EH. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14:608-16; PMID:12231357; http://dx.doi.org/10.1016/S0955-0674(02)00361-7
   PubMed Web of Science ®Google Scholar
• Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11:531-7; PMID:15821746; http://dx.doi.org/10.1038/nm1230
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, et al. Mechanisms of cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther 2008; 7:180-8; PMID:18059193; http://dx.doi.org/10.4161/cbt.7.2.5253
   PubMed Web of Science ®Google Scholar
• Kawano Y, Kypta R. Secreted antagonists of the wnt signalling pathway. J Cell Sci 2003; 116:2627-34; PMID:12775774; http://dx.doi.org/10.1242/jcs.00623
   PubMed Web of Science ®Google Scholar
• Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34:337-43; PMID:12819783; http://dx.doi.org/10.1038/ng1183
   PubMed Web of Science ®Google Scholar
• Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007; 67:10117-22; PMID:17974952; http://dx.doi.org/10.1158/0008-5472.CAN-07-2544
   PubMed Web of Science ®Google Scholar
• Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 2009; 11:126-35; PMID:19177197
   PubMed Web of Science ®Google Scholar
• Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M. HOXA11 DNA methylation–a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008; 123:725-9; PMID:18478570; http://dx.doi.org/10.1002/ijc.23563
   PubMed Web of Science ®Google Scholar
• Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 2012; 124:582-8; PMID:22115852; http://dx.doi.org/10.1016/j.ygyno.2011.11.026
   PubMed Web of Science ®Google Scholar
• Chen H, Ye F, Zhang J, Lu W, Cheng Q, Xie X. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. Eur J Gynaecol Oncol 2007; 28:464-7; PMID:18179137
   PubMed Web of Science ®Google Scholar
• Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104:1924-30; PMID:16134181; http://dx.doi.org/10.1002/cncr.21397
   PubMed Web of Science ®Google Scholar
• He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67:11099-101; PMID:18056431; http://dx.doi.org/10.1158/0008-5472.CAN-07-2672
   PubMed Web of Science ®Google Scholar
• Agostini M, Knight RA. miR-34: From bench to bedside. Oncotarget 2014; 5:872-81; PMID:24657911
   PubMed Web of Science ®Google Scholar
• Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: Modifications, screening, and therapy. Annu Rev Med 2008; 59:267-80; PMID:17937590; http://dx.doi.org/10.1146/annurev.med.59.061606.095816
   PubMed Web of Science ®Google Scholar
• Sun Y, Cao S, Yang M, Wu S, Wang Z, Lin X, Song X, Liao DJ. Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4. Oncogene 2013; 32:1794-810; PMID:22614021; 10.1038/onc.2012.200.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang M, Xi B, Xue J, He D, Zhang J, Zhao Y. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One 2012; 7:e42413; PMID:22879971; http://dx.doi.org/10.1371/journal.pone.0042413
   PubMedGoogle Scholar
• Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest 2012; 122:3603-17; PMID:22945634; http://dx.doi.org/10.1172/JCI62229
   PubMed Web of Science ®Google Scholar
• Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010; 70:277-308; PMID:20920752; http://dx.doi.org/10.1016/B978-0-12-380866-0.60010-1
   PubMed Web of Science ®Google Scholar
• Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104:1924-1930; PMID:16134181; http://dx.doi.org/10.1002/cncr.21397
   PubMed Web of Science ®Google Scholar
• Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Joensuu EI, Jarvinen HJ, Mecklin JP, Aarnio M, Peltomaki PT. Differential cancer predisposition in lynch syndrome: Insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008; 29:1351-9; PMID:18550572; http://dx.doi.org/10.1093/carcin/bgn133
   PubMed Web of Science ®Google Scholar
• Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruine AP, et al. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis 2009; 30:1041-8; PMID:19329758; 10.1093/carcin/bgp073.
   PubMed Web of Science ®Google Scholar
• Nymark P, Lindholm PM, Korpela MV, Lahti L, Ruosaari S, Kaski S, Hollmen J, Anttila S, Kinnula VL, Knuutila S. Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics 2007; 8:62; PMID:17331233; http://dx.doi.org/10.1186/1471-2164-8-62
   PubMed Web of Science ®Google Scholar